Annals of Oncology Advance Access originally published online on February 17, 2005
Annals of Oncology 2005 16(3):481-488; doi:10.1093/annonc/mdi098
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Cancer incidence and mortality in Europe, 2004
International Agency for Research on Cancer, Lyon, France
* Correspondence to: Professor P. Boyle, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France. Tel: +33-4-7273-8577; Fax: +33-4-7273-8575; Email: director{at}iarc.fr
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and methodsResultsDiscussionReferences |
|---|
Background: There are no recent estimates of the incidence and mortality from cancer at a European level. Those data that are available generally refer to the mid-1990s and are of limited use for cancer control planning. We present estimates of the cancer burden in Europe in 2004, including data for the (25 Member States) European Union.
Methods: The most recent sources of incidence and mortality data available in the Descriptive Epidemiology Group at IARC were applied to population projections to derive the best estimates of the burden of cancer, in terms of incidence and mortality, for Europe in 2004.
Results: In 2004 in Europe, there were an estimated 2 886 800 incident cases of cancer diagnosed and 1 711 000 cancer deaths. The most common incident form of cancer was lung cancer (13.3% of all incident cases), followed by colorectal cancer (13.2%) and breast cancer (13%). Lung cancer was also the most common cause of cancer death (341 800 deaths), followed by colorectal (203 700), stomach (137 900) and breast (129 900).
Conclusions: With an estimated 2.9 million new cases (54% occurring in men, 46% in women) and 1.7 million deaths (56% in men, 44% in women) each year, cancer remains an important public health problem in Europe, and the ageing of the European population will cause these numbers to continue to increase even if age-specific rates remain constant. To make great progress quickly against cancer in Europe, the need is evident to make a concerted attack on the big killers: lung, colorectal, breast and stomach cancer. Stomach cancer rates are falling everywhere in Europe and public health measures are available to reduce the incidence and mortality of lung cancer, colorectal cancer and breast cancer.
Key words: cancer, deaths, Europe, European Union, incidence
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
Currently, the most recent comprehensive estimates of the incidence and mortality from cancer at a European level can be extracted from the GLOBOCAN 2002 project of IARC [1
], but there is still no way of monitoring the evolution of the burden at the European level. In 1989, the European Network of Cancer Registries (ENCR) was established within the framework of the Europe Against Cancer programme of the European Commission. One of the objectives was to provide regular information on the burden of cancer in the European Union. Starting from 1995 [2], the ENCR published regular estimates of the incidence and prevalence of, and mortality from, cancer in the European Union using the EUCAN software [3]. The ENCR activities have, however, been interrupted, so that the latest estimates available are not sufficiently recent for today's cancer control and planning.
An attempt has been made to monitor the evolution of cancer mortality in the European Union, where it was observed that the expected number of cancer deaths in the 15 Member State European Union fell by over 9% between 1985 and 2000 [4]. During the lifetime of the Europe Against Cancer programme, favourable trends in cancer mortality were established for several common forms of cancer death in many countries [4], which appear likely to continue in the near future [5], although there were notable exceptions including lung cancer in women and most forms of cancer in Spain and Portugal [4].
In the year 2000, there were 1 122 000 deaths from cancer recorded in the 25 Member States that now constitute the European Union [5]. Even if the age-specific cancer mortality rates remain constant at year 2000 levels, there will be large increases in the absolute numbers of cancer cases and deaths into the foreseeable future. Although the total population will remain fairly constant, compared with 2000, by 2015 there will be a 22% increase in the population aged >65 years and a 50% increase in the number of persons aged >80 years. Given the strong association between cancer risk and age, this will lead to a major increase in the cancer burden. Using population projections, if the age-specific death rates remain constant, the absolute numbers of cancer deaths in 2015 will increase to 1 405 000. Even if the forecast trends are taken into account, it is still expected that there will be an increase, but this will be smaller and result in an estimated figure of 1 249 000 cancer deaths [5].
Estimates of the numbers of cancer cases and deaths in Europe for 2004 have been calculated to provide information on the cancer burden in Europe and to allow monitoring of the evolution of the impact of the ageing of the European population.
|
Materials and methods |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
The methods used to compute the estimates for major cancers are described in detail in GLOBOCAN 2002 [1
]. In summary, we estimated incidence and mortality rates (number of cases or deaths per 100 000 persons per year) for 40 European countries, by sex and cancer site, for eight age groups (0–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74 and 75+ years) using the most recent data collected by the Descriptive Epidemiology Group at IARC. The numbers of cases and deaths were computed by multiplying these estimated rates by the year 2004 population estimates for the corresponding country [6]. The results are presented for three areas: the 25 Member States of the European Union (Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, The Netherlands and the UK), the European Economic Area (the 25 European Union countries plus Iceland, Liechtenstein and Norway) plus Switzerland; and Europe (European Economic Area plus Bulgaria, Belarus, Moldova, Romania, Russian Federation, Ukraine, Albania, Bosnia and Herzegovina, Macedonia, Serbia and Montenegro and Switzerland). Because of the lack of information on cancer mortality in Eastern European countries, the results for Europe can only be presented for a limited number of cancer sites or group of sites.
Mortality data
WHO mortality data [7] are available by sex and cancer site up to 2002 for all countries in Europe, except Cyprus, Liechtenstein, and Bosnia and Herzegovina. For some Eastern European countries (Belarus, Russian Federation, Serbia and Montenegro, and Ukraine), mortality statistics are only available by an ICD-9 ‘Special Coding List’.
We estimated mortality in Cyprus using incidence and survival [8] (pooled European survival from the EUROCARE-3 study), and as the simple average of the mortality rates of neighbouring countries for Bosnia and Herzegovina, and for Liechtenstein (Table 1). For Albania, mortality rates are known to be under-estimates of the true mortality, so the rates have been corrected (multiplied by the estimated percentage of under-registration).
|
Incidence data
The methods used to estimate the sex- and age-specific incidence rates of cancer for a country fall into one of the following categories.
- National incidence data. ‘Recent’ national incidence rates are available for: Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Iceland, Finland, Ireland, Malta, Norway, Slovenia, Sweden, The Netherlands, Ukraine and the UK. National incidence rates for Belarus, Latvia, Lithuania and Slovakia have been published earlier in Cancer Incidence in Five Continents Vol. VIII [9] (Table 1). National data are also available for Austria and Poland, but have not been used as they did not meet the data quality standards required for inclusion in Cancer Incidence in Five Continents Vol. VIII.
- National mortality data. For the other countries for which national mortality is available (such as France, Germany or Italy), national incidence (IN) can be estimated by applying a set of age-, sex- and site-specific incidence/mortality ratios (IR/MR), obtained from the aggregation of representative cancer registry data, to the country's national mortality (MN): IN = MN x IR/MR. The IR/MR ratios are obtained from a Poisson regression model of the selected registry incidence data offset by corresponding mortality data, including terms for sex and age. Fifteen models have been established, based upon the most recent incidence and mortality data from local and national European cancer registries available in the EUROCIM database [10] of the ENCR. This method is regularly used by the Descriptive Epidemiology Group of IARC, and has been shown to estimate cancer incidence accurately [2].
- Local (regional) incidence data. For Serbia and Montenegro the estimates were derived from the data of two cancer registries covering a part of the country [10].
- No data. For Bosnia and Herzegovina, and for Liechtenstein, the country-specific rates were calculated from the simple average of those of neighbouring countries (Albania, Macedonia, and Serbia and Montenegro; Austria, Belgium, France, Germany, Luxembourg and Switzerland, respectively).
Population data
Estimates of the population of country (by age and sex) for the years 2000 and 2005 were taken from the United Nations population division (the 2002 revision). The 2004 population figures were estimated by calculating the annual percentage change by sex and age between the year 2000 and 2005.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
In 2004 in Europe, there were an estimated 2 886 800 incident cases of cancer diagnosed (Table 2) and 1 711 000 cancer deaths (Table 3). The most common incident form of cancer in Europe in 2004 was lung cancer (381 500 cases, 13.2% of all incident cases), followed by colorectal cancer (376 400, 13%) and breast cancer (370 100, 12.8%) (Figure 1). Lung cancer was also the largest cause of cancer death (341 800 deaths, 20% of all deaths), followed by colorectal (203 700, 11.9%), stomach (137 900, 8.1%) and breast (129 900, 7.6%) (Figure 2).
|
|
|
|
In men, there were an estimated 1 534 700 incident cases of cancer of all forms (except non-melanoma skin cancer) diagnosed. There were 298 600 new cases of lung cancer (19.4%), and prostate cancer was the second most frequent incident form of cancer in men with 237 800 new cases estimated (15.5%). There were 197 200 new cases of colorectal cancer (12.8%) and, despite its falling incidence and mortality, there were 102 800 new cases of stomach cancer (6.7%) (Table 4A). Mortality reflects the cancer prognosis, and in men there were 962 600 cancer deaths recorded (Table 5A), of which over one-quarter (268 300) were lung cancer, by far the most common cause of death. Colorectal cancer was the second major cancer killer in men with an estimated 103 300 deaths from this cause (10.7%). This was followed by prostate cancer, with 85 200 deaths estimated (8.9%).
|
|
In women, breast cancer was by far the most common incident form of cancer, with an estimated 370 100 new cases diagnosed (27.4% of all incident cases in women). Colorectal cancer was the second most common incident form of cancer in women (179 200, 13.25%), followed by cancer of the uterus, cervix and corpus combined, of which 133 800 cases were recorded (9.9%). There were an estimated 82 900 new cases of lung cancer diagnosed in women in Europe (Table 4B).
|
Breast cancer was also the most common form of cancer death in women in Europe, with 129 900 deaths (17.4%). There were 100 400 deaths from colorectal cancer (13.4%) and 73 500 deaths from lung cancer (9.8%) (Table 5B).
|
European Union
In the European Union, there were over two million (2 060 400) incident cases of cancer in 2004 and over one million cancer deaths (1 161 300).
Prostate cancer was the most common form of cancer in men (202 100 incident cases, 18.1% of all incident cases), closely followed by lung cancer (196 100, 17.6%). Colorectal cancer ranked third (149 400 cases, 13.4%), followed by bladder cancer, the fourth most common, with 91 000 (8.2%) new cases. However, due to differences in coding practices between European countries, the rubric ‘bladder cancer’ includes non-invasive tumours. Stomach cancer (53 800 cases) was slightly more common than oral cavity cancer (52 500) (Table 4A). In women, with an 8% lifetime risk, breast cancer was the most common incident form of cancer (275 100 cases, 29% of all incident cases), while colorectal cancer was second (129 800, 13.7%). There were 81 500 (8.6%) cases of uterus cancer and 62 000 (6.5%) incident cases of lung cancer (Table 4B).
Lung cancer continued to be the most common cause of cancer death in men in the European Union, with 178 400 deaths estimated in 2004 (27.3% of all cancer deaths), and the lifetime risk of dying of 5.5%. Colorectal cancer ranked second (72 300 deaths, 11.1%), followed by prostate cancer (68 200, 10.4%). In women, breast cancer is the leading cause of death in the European Union (88 400 deaths, 17.4% of total). Colorectal cancer was the second most common cause of cancer death (67 000, 13.2%), with lung cancer clearly established as the third most frequent cause of cancer deaths in women (55 900 deaths, 11%) (Table 5B).
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
With 2 886 800 incident cases and 1 711 000 deaths in 2004, cancer remains an important public health problem in Europe, and the ageing of the European population will cause these numbers to continue to increase even if age-specific rates remain constant [5
]. Lung, colorectal and breast cancer represent the three most common incident forms of cancer, accounting for two-fifths of the total European cancer burden (Table 2). Lung, colorectum, stomach and breast cancers account for nearly half of all cancer deaths in Europe (Table 3).
The estimates provided herein give a good indication of the burden of cancer incidence and death throughout Europe, and help clarify the priorities for cancer control action. The overwhelming majority of lung cancer is caused by tobacco smoking [11, 12] and tobacco control is clearly a number one priority in Europe, aimed not only at men, but increasingly targeted towards women.
Although there have been recent declines in breast cancer mortality rates in some European Union countries [4], breast cancer remains of key importance to public health in Europe. Prospects for primary prevention are unclear at present and tamoxifen no longer appears to be a candidate for chemoprevention in the general population of women [13]. Population screening with mammography is effective at reducing mortality when quality control procedures are in place [14] and there are slow but continual increases taking place in treatment outcome [15], reflected by the very high ratio of the lifetime risk of getting the disease (7.8%) to that of dying from the disease (2%) observed in the European Union. However, there is still a clear need to accelerate prospects for preventing women getting breast cancer as well as dying from the disease.
Colorectal cancer is the third most common form of cancer in men and the second most common form of cancer in women in Europe, but it ranked second in frequency of deaths in both men and women. The potential to avoid many deaths from colorectal cancer has been available for several years [16, 17], although progress in implementing what is known has been remarkably slow.
What is very clear is that if we wish to make great progress quickly against cancer in Europe, then the need is evident to make a concerted attack on the big killers: lung, colorectal, breast and stomach cancer.
Thankfully, stomach cancer incidence and mortality are declining throughout Europe, in both men and women [4]. Lung cancer incidence and mortality will be reduced by effective tobacco control, and while there has been substantial progress in men in Europe, the situation in women, particularly young women, is cause for concern. Furthermore, the situation differs greatly between Northern Europe and Central and Eastern Europe (Figure 3) and the latter region should be a special target for tobacco control.
|
The introduction of organised mammographic screening programmes throughout Europe will lead to a reduction in breast cancer mortality. The maximum effect will be derived from programmes with effective quality control procedures in place. Similarly, screening for colorectal cancer has been shown to be effective [18
] and there is a need for organised colorectal cancer screening programmes throughout Europe.
These are among the key recommendations of the recently revised European Code Against Cancer, which provides a public health roadmap for cancer risk reduction in Europe [18].
Received for publication December 7, 2004. Accepted for publication December 9, 2004.
|
References |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence. Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0., Lyon: IARC Press 2004.
2. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99–166.[CrossRef][Web of Science][Medline]
3. Ferlay J, Bray F, Sankila R, Parkin DM. EUCAN: Cancer Incidence. Mortality and Prevalence in the European Union 1998. IARC CancerBase No. 4, version 5.0. Lyon: IARC Press 1999.
4. Boyle P, d'Onofrio A, Maisonneuve P et al. Measuring progress against cancer in Europe: has the 15% decline targeted for 2000 come about? Ann Oncol 2003; 14: 1312–1325.
5. Quinn MJ, d'Onofrio A, Moller B et al. Cancer mortality trends in EU and acceeding countries. Ann Oncol 2003; 14: 1148–1152.
6. United Nations, Population Division. World Population Prospects (2002 revision). Available online at: http://www.un.org/ (date last accessed 30 August, 2004).
7. WHO. World Health Organisation Databank, Geneva, Switzerland. WHO Statistical Information System. Available online at: http://www.who.int/whosis (date last accessed 20 July, 2004).
8. The EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94. Results and commentary. Ann Oncol 2003; 14: v61–v118.[CrossRef][Medline]
9. Parkin DM, Whelan SL, Ferlay J, et al. (eds) Cancer Incidence in Five Continents, Vol. VIII. IARC Scientific Publications No. 155, Lyon: IARC Press 2002.
10. EUROCIM version 4.1. European Incidence Database V2.4, ICD-10 Entity Dictionary. Lyon 2003.
11. International Agency for Research on Cancer (IARC). Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 83. Tobacco Smoke and Involuntary Smoking, Lyon: IARC Press 2004.
12. Boyle P, Gray N, Zatonski W, et al. Tobacco: Science, Policy and Public Health. Oxford: Oxford University Press 2003.
13. Cuzick J, Powles T, Veronesi U et al. Overview of main outcomes in breast cancer prevention trials. Lancet 2003; 361: 296–300.[CrossRef][Web of Science][Medline]
14. IARC Handbook of Cancer Prevention, Vol. 70 Breast Cancer Screening. Lyon: IARC Press 2002.
15. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001; 1: CD000486.
16. Boyle P. Progress in preventing death from colorectal cancer. Br J Cancer 1995; 72: 528–530.[Web of Science][Medline]
17. Faivre J, Dancourt V, Lejeune C et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004; 126: 1674–1680.[CrossRef][Web of Science][Medline]
18. Boyle P, Autier P, Bartelink H et al. European Code Against Cancer and scientific justification: third version. Ann Oncol 2003; 14: 973–1005.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Pellegriti, F. De Vathaire, C. Scollo, M. Attard, C. Giordano, S. Arena, G. Dardanoni, F. Frasca, P. Malandrino, F. Vermiglio, et al. Papillary Thyroid Cancer Incidence in the Volcanic Area of Sicily J Natl Cancer Inst, November 5, 2009; (2009) djp354v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. de Vos, A. Goy, S. R. Dakhil, M. N. Saleh, P. McLaughlin, R. Belt, C. R. Flowers, M. Knapp, L. Hart, D. Patel-Donnelly, et al. Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma J. Clin. Oncol., October 20, 2009; 27(30): 5023 - 5030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pfost, C. Seidl, M. Autenrieth, D. Saur, F. Bruchertseifer, A. Morgenstern, M. Schwaiger, and R. Senekowitsch-Schmidtke Intravesical {alpha}-Radioimmunotherapy with 213Bi-Anti-EGFR-mAb Defeats Human Bladder Carcinoma in Xenografted Nude Mice J. Nucl. Med., October 1, 2009; 50(10): 1700 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. J. Van Hemelrijck, D. S. Michaud, G. N. Connolly, and Z. Kabir Tobacco use and bladder cancer patterns in three western European countries J. Public Health Med., September 1, 2009; 31(3): 335 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Postma, M. Koopman, T. E. Buffart, P. P. Eijk, B. Carvalho, G. J. Peters, B. Ylstra, J. H. van Krieken, C. J. A. Punt, and G. A. Meijer DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer Ann. Onc., June 1, 2009; 20(6): 1048 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. ZEIDAN, R. I. CUTRESS, N. MURRAY, G. R. COULTON, C. HASTIE, G. PACKHAM, and P. A. TOWNSEND Proteomic Analysis of Archival Breast Cancer Serum Cancer Genomics Proteomics, May 1, 2009; 6(3): 141 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Ruiz, X. Sui, F. Lobelo, D.-c. Lee, J. R. Morrow Jr., A. W. Jackson, J. R. Hebert, C. E. Matthews, M. Sjostrom, and S. N. Blair Muscular Strength and Adiposity as Predictors of Adulthood Cancer Mortality in Men Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1468 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Poschmann, B. Sitek, B. Sipos, A. Ulrich, S. Wiese, C. Stephan, B. Warscheid, G. Kloppel, A. Vander Borght, F. C. S. Ramaekers, et al. Identification of Proteomic Differences between Squamous Cell Carcinoma of the Lung and Bronchial Epithelium Mol. Cell. Proteomics, May 1, 2009; 8(5): 1105 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stahl, J. Oliveira, and On behalf of the ESMO Guidelines Working Group Esophageal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv32 - iv33. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ludwig, R. Hajek, E. Tothova, J. Drach, Z. Adam, B. Labar, M. Egyed, I. Spicka, H. Gisslinger, R. Greil, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma Blood, April 9, 2009; 113(15): 3435 - 3442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J.J. Van Hemelrijck, D. S. Michaud, G. N. Connolly, and Z. Kabir Secondhand Smoking, 4-Aminobiphenyl, and Bladder Cancer: Two Meta-analyses Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1312 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ouwens, M. Hulscher, R. Hermens, M. Faber, H. Marres, H. Wollersheim, and R. Grol Implementation of integrated care for patients with cancer: a systematic review of interventions and effects Int. J. Qual. Health Care, April 1, 2009; 21(2): 137 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-F. Etter Perceived priorities for prevention: change between 1996 and 2006 in a general population survey J. Public Health Med., March 1, 2009; 31(1): 113 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Attard, A. H.M. Reid, T. A. Yap, F. Raynaud, M. Dowsett, S. Settatree, M. Barrett, C. Parker, V. Martins, E. Folkerd, et al. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven J. Clin. Oncol., October 1, 2008; 26(28): 4563 - 4571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Palumbo, F. Gay, S. Bringhen, A. Falcone, N. Pescosta, V. Callea, T. Caravita, F. Morabito, V. Magarotto, M. Ruggeri, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma Ann. Onc., June 1, 2008; 19(6): 1160 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Khan, V. Gallo, J. Linseisen, R. Kaaks, S. Rohrmann, O. Raaschou-Nielsen, A. Tjonneland, H. E. Johnsen, K. Overvad, M. M. Bergmann, et al. Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition Haematologica, June 1, 2008; 93(6): 842 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Kozuch, C. M. Rocha-Lima, T. Dragovich, H. Hochster, B. H. O'Neil, O. T. Atiq, J. M. Pipas, D. P. Ryan, and H.-J. Lenz Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II Study J. Clin. Oncol., May 10, 2008; 26(14): 2320 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nieters, S. Rohrmann, N. Becker, J. Linseisen, T. Ruediger, K. Overvad, A. Tjonneland, A. Olsen, N. E. Allen, R. C. Travis, et al. Smoking and Lymphoma Risk in the European Prospective Investigation into Cancer and Nutrition Am. J. Epidemiol., May 1, 2008; 167(9): 1081 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Persson, U Ostlund, A Wennman-Larsen, Y Wengstrom, and P Gustavsson Health-related quality of life in significant others of patients dying from lung cancer Palliative Medicine, April 1, 2008; 22(3): 239 - 247. [Abstract] [PDF]
|
|
|
|
|
|
R. A.C. Ruiter, J. de Nooijer, G. van Breukelen, C. F. Ockhuysen-Vermey, and H. de Vries Intended Coping Responses to Cancer Symptoms in Healthy Adults: The Roles of Symptom Knowledge, Detection Behavior, and Perceived Threat Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 818 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Martinez-Torrecuadrada, L. H. Cheung, P. Lopez-Serra, R. Barderas, M. Canamero, S. Ferreiro, M. G. Rosenblum, and J. I. Casal Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis Mol. Cancer Ther., April 1, 2008; 7(4): 862 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bosetti, P. Bertuccio, F. Levi, F. Lucchini, E. Negri, and C. La Vecchia Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis Ann. Onc., April 1, 2008; 19(4): 631 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Boyle Favorable trends in cancer mortality in the European Union but no room for complacency Ann. Onc., April 1, 2008; 19(4): 605 - 606. [Full Text] [PDF]
|
|
|
|
|
|
D. Connolly, A. Black, A. Gavin, P. F. Keane, and L. J. Murray Baseline Prostate-Specific Antigen Level and Risk of Prostate Cancer and Prostate-Specific Mortality: Diagnosis Is Dependent on the Intensity of Investigation Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Dabakuyo, F. Bonnetain, P. Roignot, M.-L. Poillot, G. Chaplain, T. Altwegg, G. Hedelin, and P. Arveux Population-based study of breast cancer survival in Cote d'Or (France): prognostic factors and relative survival Ann. Onc., February 1, 2008; 19(2): 276 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lidgren, B. Jonsson, C. Rehnberg, N. Willking, and J. Bergh Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer Ann. Onc., December 6, 2007; (2007) mdm488v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dimopoulos, A. Spencer, M. Attal, H. M. Prince, J.-L. Harousseau, A. Dmoszynska, J. S. Miguel, A. Hellmann, T. Facon, R. Foa, et al. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma N. Engl. J. Med., November 22, 2007; 357(21): 2123 - 2132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Troiani, N. J. Serkova, D. L. Gustafson, T. K. Henthorn, O. Lockerbie, A. Merz, M. Long, M. Morrow, F. Ciardiello, and S. G. Eckhardt Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model Clin. Cancer Res., November 1, 2007; 13(21): 6450 - 6458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B Ballinger and C. Anggiansah Colorectal cancer BMJ, October 6, 2007; 335(7622): 715 - 718. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tot The Theory of the Sick Breast Lobe and the Possible Consequences International Journal of Surgical Pathology, October 1, 2007; 15(4): 369 - 375. [Abstract] [PDF]
|
|
|
|
|
|
A. Palumbo, P. Falco, P. Corradini, A. Falcone, F. Di Raimondo, N. Giuliani, C. Crippa, G. Ciccone, P. Omede, M. T. Ambrosini, et al. Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network J. Clin. Oncol., October 1, 2007; 25(28): 4459 - 4465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Arbyn, A. O. Raifu, P. Autier, and J. Ferlay Burden of cervical cancer in Europe: estimates for 2004 Ann. Onc., October 1, 2007; 18(10): 1708 - 1715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Klaeser, O Wiederkehr, D Koeberle, A Mueller, B Bubeck, and B Thuerlimann Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer Ann. Onc., August 1, 2007; 18(8): 1329 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Arbyn, P Autier, and J Ferlay Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004 Ann. Onc., August 1, 2007; 18(8): 1423 - 1425. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Manochakian, K. C. Miller, and A. A. Chanan-Khan Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma Oncologist, August 1, 2007; 12(8): 978 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. O'Dwyer, S. G. Eckhardt, D. G. Haller, J. Tepper, D. Ahnen, S. Hamilton, A. B. Benson III, M. Rothenberg, N. Petrelli, H.-J. Lenz, et al. Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups J. Clin. Oncol., June 1, 2007; 25(16): 2313 - 2321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Borget, C Corone, M Nocaudie, M Allyn, S Iacobelli, M Schlumberger, and G De Pouvourville Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal Eur. J. Endocrinol., May 1, 2007; 156(5): 531 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Demirkan, A. Alacacioglu, and U. Yilmaz Relation of Body Mass Index (BMI) to Disease Free (DFS) and Distant Disease Free Survivals (DDFS) Among Turkish Women with Operable Breast Carcinoma Jpn. J. Clin. Oncol., April 1, 2007; 37(4): 256 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Barrabes, L. Pages-Pons, C. M. Radcliffe, G. Tabares, E. Fort, L. Royle, D. J. Harvey, M. Moenner, R. A. Dwek, P. M. Rudd, et al. Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer Glycobiology, April 1, 2007; 17(4): 388 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Boncz, A Sebestyen, L Dobrossy, Z Pentek, A Budai, A Kovacs, C Dozsa, and I Ember The organisation and results of first screening round of the Hungarian nationwide organised breast cancer screening programme Ann. Onc., April 1, 2007; 18(4): 795 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Ferlay, P Autier, M Boniol, M Heanue, M Colombet, and P Boyle Estimates of the cancer incidence and mortality in Europe in 2006 Ann. Onc., March 1, 2007; 18(3): 581 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. de Bono, J. Bellmunt, G. Attard, J. P. Droz, K. Miller, A. Flechon, C. Sternberg, C. Parker, G. Zugmaier, V. Hersberger-Gimenez, et al. Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer J. Clin. Oncol., January 20, 2007; 25(3): 257 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Cleries, J Ribes, L Esteban, J. Martinez, and J. Borras Time trends of breast cancer mortality in Spain during the period 1977-2001 and Bayesian approach for projections during 2002-2016 Ann. Onc., December 1, 2006; 17(12): 1783 - 1791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Cai, Y.-T. Gao, W.-H. Chow, X.-O. Shu, G. Yang, B.-T. Ji, W. Wen, N. Rothman, H.-L. Li, J. D. Morrow, et al. Prospective Study of Urinary Prostaglandin E2 Metabolite and Colorectal Cancer Risk J. Clin. Oncol., November 1, 2006; 24(31): 5010 - 5016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Fanucchi, F. V. Fossella, R. Belt, R. Natale, P. Fidias, D. P. Carbone, R. Govindan, L. E. Raez, F. Robert, M. Ribeiro, et al. Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., November 1, 2006; 24(31): 5025 - 5033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. I. Fisher, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al. Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma J. Clin. Oncol., October 20, 2006; 24(30): 4867 - 4874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Gabriel, A. zur Hausen, E. Stickeler, C. Dietz, G. Gitsch, D.-C. Fischer, J. Bouda, C. Tempfer, and A. Hasenburg Weak Expression of Focal Adhesion Kinase (pp125FAK) in Patients with Cervical Cancer Is Associated with Poor Disease Outcome Clin. Cancer Res., April 15, 2006; 12(8): 2476 - 2483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Savage, L. Hou, J. Lissowska, W.-H. Chow, W. Zatonski, S. J. Chanock, and M. Yeager Interleukin-8 polymorphisms are not associated with gastric cancer risk in a polish population. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 589 - 591. [Full Text] [PDF]
|
|
|
|
|
|
A. Tavani, L. Giordano, S. Gallus, R. Talamini, S. Franceschi, A. Giacosa, M. Montella, and C. La Vecchia Consumption of sweet foods and breast cancer risk in Italy Ann. Onc., February 1, 2006; 17(2): 341 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Van Cutsem and F. Costa Progress in the Adjuvant Treatment of Colon Cancer: Has It Influenced Clinical Practice? JAMA, December 7, 2005; 294(21): 2758 - 2760. [Full Text] [PDF]
|
|
|
|
|
|
T. Fisch, P. Pury, N. Probst, A. Bordoni, C. Bouchardy, H. Frick, G. Jundt, D. De Weck, E. Perret, and J.-M. Lutz Variation in survival after diagnosis of breast cancer in Switzerland Ann. Onc., December 1, 2005; 16(12): 1882 - 1888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-M. Kim, S.-H. Yim, J.-S. Lee, M.-S. Kwon, J.-W. Ryu, H.-M. Kang, H. Fiegler, N. P. Carter, and Y.-J. Chung Genome-Wide Screening of Genomic Alterations and Their Clinicopathologic Implications in Non-Small Cell Lung Cancers Clin. Cancer Res., December 1, 2005; 11(23): 8235 - 8242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and and Panel Members Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 Ann. Onc., October 1, 2005; 16(10): 1569 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Andre and W Schmiegel CHEMORADIOTHERAPY FOR COLORECTAL CANCER Gut, August 1, 2005; 54(8): 1194 - 1202. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tefferi, S. V. Rajkumar, and A. A. Adjei Introduction to a Cancer Symposium for the Practitioner Mayo Clin. Proc., August 1, 2005; 80(8): 1085 - 1086. [PDF]
|
|
|
|
|
|
E. Kralikova, E. Podmaniczky, H. Stypulkowska-Misiurewicz, E. Kavcova, A. Veryga, and T. Muller Making the transition to action BMJ, July 23, 2005; 331(7510): 191 - 192. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||